There is a trend at the end of each year followed by many income investors. This is the Dogs of the Dow, which is simply made up of the 10 Dow Jones Industrial Average (DJIA) components that have the highest common stock dividend yields. This is widely followed at the start and end of each year, but it has merit all throughout each year because these companies attract so many different dividend strategy investors.
The following look as though they will be the top five Dogs of the Dow for 2014: AT&T Inc. (NYSE: T), Verizon Communications Inc. (NYSE: VZ), Intel Corp. (NASDAQ: INTC), Merck & Co. Inc. (NYSE: MRK), McDonald’s Corp. (NYSE: MCD) and Chevron Corp. (NYSE: CVX).
24/7 Wall St. has identified the basics on each component for these 10 Dogs of the Dow. We have also given color on each to see what could drive each one higher or lower in 2014. All these companies are systemically important�or they�are sector movers on their own right.
Another issue to consider for 2014 is that there will be some serious changes to the Dogs of the Dow, barring any major performance changes in the final three weeks of 2013. Consensus estimates were also based on Thomson Reuters data.
Best Industrial Conglomerate Companies To Watch In Right Now: Altria Group(MO)
Altria Group, Inc., through its subsidiaries, engages in the manufacture and sale of cigarettes, smokeless products, and wine in the United States and internationally. It offers cigarettes under the Marlboro, Virginia Slims, Parliament, Benson & Hedges, Basic, and L&M brands; smokeless tobacco products under the Copenhagen, Skoal, Red Seal, Husky brands, and Marlboro snus brands; and machine-made large cigars and pipe tobacco. The company also produces and sells blended table wines under the Chateau Ste Michelle and Columbia Crest names; and distributes Antinori and Villa Maria Estate wines and Champagne Nicolas Feuillatte in the United States. In addition, it maintains a portfolio of leveraged and direct finance leases in rail and surface transport, aircraft, electric power, real estate, and manufacturing. The company sells its tobacco products to wholesalers, including distributors; large retail organizations, such as chain stores; and the armed services. Altria Group, Inc. markets its wine products to restaurants, wholesale clubs, supermarkets, wine shops, and mass merchandisers. The company was founded in 1919 and is headquartered in Richmond, Virginia.
Advisors' Opinion:- [By Patricio Kehoe] ynolds American Inc. (RAI) and Lorillard Inc. (LO). In addition to the popularity of its brands, Phillip Morris benefits from scale advantages, combined with the historically strong brand loyalty among smokers, earning the firm strong pricing power. This advantage has allowed revenue to nearly double since 2006, leaving its current level of $77.4 billion.
Regarding Taxes, Regulations and Margins
Despite recent anti-tobacco laws passed by the European Union and the Food and Drug Administration (FDA) in the U.S, the company�� pricing power has helped maintain its margins. In 2012, for example, Phillip Morris hiked prices on its products in Russia, Germany, Belgium, Canada, France, Greece and Spain, among others. Although the necessary measure caused substantial volume declines in these countries, consumers rapidly became accustomed to the increased prices, and returned to their habitual product consumption. Given the success of this strategy, the firm is likely to rely on it in Japan for 2014, where taxes are expected to increase yet again by 8%, after the 40% spike in October 2010.
Another profitable business opportunity may come from the company�� recent cross-licensing agreement with its parent firm Altria, regarding next-generation products. The deal will allow Phillip Morris to market Altria�� eCig products outside the U.S, while the parent firm commercializes the tobacco giant�� two heated tobacco products, Platform 1 and Platform 2, within the U.S. Platform 1 is meant to launch in 2014, and Platform 2 a year later, which should help the company branch out to changing consumer habits among smokers and generate further revenue. On another note, Phillip Morris��shareholder returns should not pass unseen by investors. Since 2008, the company has returned $59.1 billion to its investors via share repurchases ($27.9) and dividends ($24), and currently holds a steady dividend yield of 4.39%.
Bottom Line
With an EPS growth of
- [By Muhammad Bazil]
Altria Group Inc (MO) is a producer of cigarettes and other tobacco related products. Two of its competitors include; British American Tobacco (ADR) (BTI) and Imperial Tobacco Group Plc (ADR) (ITYBY)
- [By Selena Maranjian]
Let's run through an example: domestic tobacco giant Altria (NYSE: MO ) .
Why Altria?
The company is what's left after international operations were spun off in the form of Philip Morris International (NYSE: PM ) in 2008. While Philip Morris is favored by many because of lower tobacco taxes and regulations in many parts of the world, as well as the fact that many economies are growing more rapidly than ours, Altria still manages the very valuable Marlboro brand domestically, where it recently held a commanding 43% market share. - [By WALLSTCHEATSHEET]
Altria Group provides cigarette, cigar, tobacco and wine products to many consumers all around the world. The stock has witnessed a strong bid higher and is now consolidating slightly below all-time high prices. Over the last four quarters, earnings and revenue figures have been on the rise which have been mostly priced-in by investors in the company. Relative to its peers and sector, Altria Group has been a year-to-date performance leader. Look for Altria Group to OUTPERFORM.
Best Dividend Companies To Watch For 2014: Paychex Inc.(PAYX)
Paychex Inc., together with its subsidiaries, provides payroll, human resource, and benefits outsourcing solutions for small-to medium-sized businesses in the United States and Germany. It offers payroll processing services, including calculation, preparation, and delivery of employee payroll checks; production of internal accounting records and management reports; preparation of federal, state, and local payroll tax returns; and collection and remittance of clients? payroll obligations. The company also provides payroll tax administration services; employee payment services; and regulatory compliance services, such as new-hire reporting and garnishment processing. Its human resource outsourcing services include payroll, employer compliance, human resource and employee benefits administration, risk management outsourcing, and the on-site availability of a professionally trained human resource representative, as well as provides employee handbooks, management manuals, and r equired regulatory forms. In addition, the company offers retirement services administration; workers? compensation; business-owner policies; commercial auto; and health and benefits coverage, including health, dental, vision, and life. Further, it provides online human resource administration software products for employee benefits management and administration, and time and attendance solutions. As of May 31, 2010, the company served approximately 536,000 clients in the United States; and 1,700 clients in Germany. Paychex, Inc. was founded in 1971 and is headquartered in Rochester, New York.
Advisors' Opinion:- [By Katie Brennan]
Paychex Inc. (PAYX) dropped 3.7 percent to $36.60. The payrolls manager reported fourth-quarter earnings per share of 34 cents, below the average analyst estimate for profit of 37 cents. Revenue in the period was $585.3 million, missing the $586.2 million average projection.
Best Dividend Companies To Watch For 2014: S&P GSCI(GD)
General Dynamics Corporation, an aerospace and defense company, provides business aviation; combat vehicles, weapons systems, and munitions; military and commercial shipbuilding; and communications and information technology products and services worldwide. Its Aerospace group designs, manufactures, and outfits various large and mid-cabin business-jet aircraft; provides maintenance, repair work, fixed-based operations, and aircraft management services; and performs aircraft completions for aircraft. The company?s Combat Systems group offers tracked and wheeled military vehicles, weapons systems, and munitions. Its product lines include wheeled combat and tactical vehicles; battle tanks and infantry vehicles; munitions and propellant; rockets and gun systems; and axle and drivetrain components and aftermarket parts. This group also manufactures and supplies engineered axles, suspensions, and brakes for heavy-load vehicles for military and commercial customers. The company Advisors' Opinion:
- [By Rich Smith]
The Department of Defense awarded more than $961 million worth of contracts to a total of 17 awardees on Thursday. Notable awards to publicly traded companies included:
- [By Rich Smith]
Perhaps appropriately for an arms merchant, General Dynamics (NYSE: GD ) stock is exploding this week, up nearly 8.8% since reporting earnings Wednesday morning -- and up about twice as much as the gains o fellow defense contractor Boeing (NYSE: BA ) , which also reported Wednesday.
- [By Eric Volkman]
General Dynamics (NYSE: GD ) is electing to keep its dividend level for the time being. The company has declared a quarterly disbursement of $0.56 per share of its common stock, to be paid on Aug. 9 to shareholders of record as of July 5.
Best Dividend Companies To Watch For 2014: Abbott Laboratories(ABT)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; dyslipidemia; HIV infection; prostate cancer, endometriosis and central precocious puberty, and anemia caused by uterine fibroids; respiratory syncytial virus; adult males who have low or no testosterone; secondary hyperparathyroidism; hypothyroidism; and pancreatic exocrine insufficiency, as well as anesthesia products. It also provides diagnostic products, such as immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-b ased tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis. In addition, the company offers a line of pediatric and adult nutritional products. Further, it provides coronary, endovascular, vessel closure, and structural heart devices, such as drug-eluting stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, carotid stent systems, percutaneous valve repair systems, and drug eluting bioresorbable vascular products. Additionally, the company provides blood glucose monitoring meters, test strips, data management software, and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, lasik surgery, contact lens, and dry eye products, as well as branded generic pharmaceutical products. Abbott primarily serves retailers, wholesalers, hospitals, and health care facilities. Abbott was founded in 1888 and is headquartered in Abbott Park, Illinois.
Advisors' Opinion:- [By Philip Springer]
This was a big week for the global pharmaceutical industry. First, rumors of one deal suggested a possible return to the industry’s old self-destructive ways. But then two other transactions were announced that signaled continuation of a newer trend that’s much healthier for shareholders.
On Monday, it was reported that New York-based Pfizer Inc. (NYSE: PFE) had been in talks to acquire AstraZeneca PLC (NYSE: AZN), headquartered in London, for over $100 billion. The companies apparently broke off the discussions.
If such a transaction were to occur, it would be the latest in a long series of megamergers that characterized the corporate strategies of Pfizer, Swiss drug giant Novartis AG (NYSE: NVS) and others in the 1990s and 2000s. Back then, the aim was to acquire rivals in multibillion-dollar deals that broadened the buyers’ businesses to cover more diseases and new health-care areas.
The catalyst for this buying binge was the so-called patent cliff, in which some of the sector’s biggest drugs faced the loss of patents that protected them from competition, resulting in reduced revenues and earnings.
Since then, however, the patent cliff problem has waned because many of those patent expirations have already occurred. And the bigger, combined companies generally have come up short on development of new blockbuster drugs. Also, excessive diversification has brought weak competitive positions in some niches.
But the current industry trend is for companies to focus more on their core strengths instead of diversifying. Pfizer, Bristol-Myers Squibb (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) have made such moves over the last few years in order to focus on what they consider higher-growth prospects.
Tuesday brought more of the same. Novartis and UK-based GlaxoSmithKline (NYSE: GSK) announced more than $20 billion in deals. Novartis is to sell its animal-drugs busi - [By Timothy Lutts]
Abbott Laboratories (ABT) is just what the doctor ordered; the 125 year-old company has a solid business with a good reputation and good long-term growth prospects.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (NYSE: ABT ) has earned a coveted five-star ranking.
No comments:
Post a Comment